Compounds > fluoxetine

fluoxetine and mitomycin

fluoxetine has been researched along with mitomycin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dekel, Y; Margalit, R; Melikhov, D; Peer, D1
Balboa, J; Brenlla, J; Freire-Garabal, M; González-Peteiro, M; Núñez, MJ; Rodrigo, E1

Reviews

1 review(s) available for fluoxetine and mitomycin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for fluoxetine and mitomycin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Cancer research, 2004, Oct-15, Volume: 64, Issue:20

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluoxetine; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitomycin; Neoplasms, Experimental; Paclitaxel; Tissue Distribution; Vinblastine; Xenograft Model Antitumor Assays

2004
Effects of fluoxetine on cellular immune response in stressed mice.
    Neuroscience letters, 2006, Apr-03, Volume: 396, Issue:3

    Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Cell Count; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Immunity, Cellular; Killer Cells, Natural; Male; Mice; Mice, Inbred BALB C; Mitomycin; Spleen; Stress, Physiological; T-Lymphocytes, Cytotoxic; Time Factors

2006